Prasad Raju 4
4 · CRISPR Therapeutics AG · Filed Jan 26, 2026
Research Summary
AI-generated summary of this filing
CRISPR Therapeutics CFO Prasad Raju Exercises Options, Sells Shares
What Happened
Prasad Raju, Chief Financial Officer of CRISPR Therapeutics (CRSP), exercised 34,972 stock options and immediately sold those 34,972 shares. He paid $45.15 per share to exercise (total cost $1,578,986) and sold the shares in the open market at a weighted average price of $60.19 for total gross proceeds of $2,104,965 — a net difference of approximately $525,979 before taxes and fees. The sales were executed pursuant to a pre-established Rule 10b5-1 trading plan.
Key Details
- Transaction date: January 22, 2026 (reported on Form 4 filed January 26, 2026 — timely).
- Exercise: 34,972 shares at $45.15/share (total $1,578,986).
- Sale: 34,972 shares at weighted avg $60.19/share (total $2,104,965); sales prices ranged $60.00–$60.42.
- Net cash difference (sale proceeds minus exercise cost): ≈ $525,979 (pre-tax, pre-fees).
- Shares owned after transaction: not specified in the provided filing.
- Notable footnotes: (F1) sales were under a 10b5-1 trading plan adopted Aug 18, 2025; (F2) reported sale price is a weighted average across multiple trades; (F3) the options were granted Mar 14, 2023 (100,000 options) with a multi-year vesting schedule.
- Filing timeliness: Form 4 filed on Jan 26, 2026, which meets the usual two-business-day filing requirement.
Context
This was an exercise-and-sell sequence (options exercised then shares sold) executed under a pre-set 10b5-1 plan, a common mechanism executives use to sell shares at predetermined times. The 10b5-1 disclosure indicates the sales were made pursuant to a prior plan rather than an ad-hoc decision; this is informational and not a statement about insider intent.
Insider Transaction Report
- Exercise/Conversion
Common Shares
2026-01-22$45.15/sh+34,972$1,578,986→ 41,739 total - Sale
Common Shares
[F1][F2]2026-01-22$60.19/sh−34,972$2,104,965→ 6,767 total - Exercise/Conversion
Stock Option (Right to Buy)
[F3]2026-01-22−34,972→ 41,667 totalExercise: $45.15Exp: 2033-03-14→ Common Shares (34,972 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]This option was granted on March 14, 2023 with respect to 100,000 Common Shares, with 25% of the shares vesting on March 14, 2024 and the remaining shares vesting on each monthly anniversary thereafter for a period of 36 months.